Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer

Abstract

Abstract:

The miR-34 family plays an important role in gastric cancer， and the inactivation or reduced expression of the miR-34 family is detected in gastric cancer cell lines and gastric cancer tissues compared with normal gastric mucosa tissues， indicating it is associated with the occurrence and development of gastric cancer. Studies have shown that miR-34 plays a key role in inhibiting gastric cancer progression by regulating IGF2BP3， survivin， Bcl-2 and epithelial-mesenchymal transition-related pathway， indicating that miR-34 is an important target for gastric cancer treatment. In terms of clinical treatment， miR-34 has not only been proved to have radiochemotherapy sensitization， but also achieved good curative effect in tumor clinical trials. With the emergence of miR-34 vectors targeting gastric cancer， it is possible to use it for gastric cancer treatment. Deep understanding of the molecular basis and clinical efficacy of miR-34 for gastric cancer treatment can help to evaluate the potential of the miR-34 family as a new therapeutic target for gastric cancer.

Key words:Gastric neoplasms,MicroRNAs,miR-34,Epithelial-mesenchymal transition

Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei. Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 681-686.

References59

[1]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474. doi:10.1097/CM9.0000000000001474
[2]	Chung HC, Bang YJ, S Fuchs C, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021, 17(5): 491-501. DOI: 10.2217/fon-2020-0737. doi:10.2217/fon-2020-0737pmid:33167735
[3]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2. doi:10.1016/S0140-6736(21)00797-2pmid:34102137
[4]	徐惠绵, 潘四维. 胃癌诊治研究进展2021年度盘点[J]. 肿瘤学杂志, 2022, 28(2): 81-85. DOI: 10.11735/j.issn.1671-170X.2022.02.B001. doi:10.11735/j.issn.1671-170X.2022.02.B001
[5]	Liu G, Jiang C, Li D, et al. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer[J]. Tumour Biol, 2014, 35(10): 9801-9806. DOI: 10.1007/s13277-014-2273-6. doi:10.1007/s13277-014-2273-6
[6]	Mirzajani E, Vahidi S, Norollahi SE, et al. Novel biomarkers of microRNAs in gastric cancer: an overview from diagnosis to treatment[J]. Microrna, 2022, 11(1): 12-24. DOI: 10.2174/2211536611666220322160242. doi:10.2174/2211536611666220322160242
[7]	Xiong S, Hu M, Li C, et al. Role of miR‑34 in gastric cancer: from bench to bedside (review)[J]. Oncol Rep, 2019, 42(5): 1635-1646. DOI: 10.3892/or.2019.7280. doi:10.3892/or.2019.7280pmid:31432176
[8]	Bonetti P, Climent M, Panebianco F, et al. Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer[J]. Oncogene, 2019, 38(3): 360-374. DOI: 10.1038/s41388-018-0445-3. doi:10.1038/s41388-018-0445-3pmid:30093634
[9]	Krajewska JB, Fichna J, Mosińska P. One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?[J]. Crit Rev Oncol Hematol, 2018(132): 1-8. DOI: 10.1016/j.critrevonc.2018.09.006. doi:10.1016/j.critrevonc.2018.09.006
[10]	Shi L, Wang Z, Geng X, et al. Exosomal miRNA-34 from cancer-associated fibroblasts inhibits growth and invasion of gastric cancer cells in vitro and in vivo[J]. Aging (Albany NY), 2020, 12(9): 8549-8564. DOI: 10.18632/aging.103157. doi:10.18632/aging.103157
[11]	Wang H, Wang F, Wang X, et al. Friend or foe: a cancer suppressor microRNA-34 potentially plays an adverse role in vascular diseases by regulating cell apoptosis and extracellular matrix degradation[J]. Med Sci Monit, 2019, 25: 1952-1959. DOI: 10.12659/MSM.915270. doi:10.12659/MSM.915270
[12]	Wang B, Li D, Kovalchuk I, et al. miR-34a directly targets tRNA_i^Metprecursors and affects cellular proliferation, cell cycle, and apoptosis[J]. Proc Natl Acad Sci U S A, 2018, 115(28): 7392-7397. DOI: 10.1073/pnas.1703029115. doi:10.1073/pnas.1703029115pmid:29941603
[13]	Zhang L, Wang L, Dong D, et al. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis[J]. Cell Prolif, 2019, 52(1): e12527. DOI: 10.1111/cpr.12527. doi:10.1111/cpr.12527
[14]	Xi L, Zhang Y, Kong S, et al. miR-34 inhibits growth and promotes apoptosis of osteosarcoma in nude mice through targetly regulating TGIF2 expression[J]. Biosci Rep, 2018, 38(3): BSR20180078. DOI: 10.1042/BSR20180078. doi:10.1042/BSR20180078
[15]	Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 53. DOI: 10.1186/s13046-019-1059-5. doi:10.1186/s13046-019-1059-5
[16]	Jafari N, Abediankenari S. MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell[J]. Tumour Biol, 2017, 39(5): 1010428317701652. DOI: 10.1177/1010428317701652. doi:10.1177/1010428317701652
[17]	Imani S, Wu RC, Fu J. MicroRNA-34 family in breast cancer: from research to therapeutic potential[J]. J Cancer, 2018, 9(20): 3765-3775. DOI: 10.7150/jca.25576. doi:10.7150/jca.25576pmid:30405848
[18]	李可心. IGF2BP3在食管鳞癌和结直肠癌中的作用及机制研究[D]. 北京: 北京协和医学院, 2020. DOI: 10.27648/d.cnki.gzxhu.2020.000169. doi:10.27648/d.cnki.gzxhu.2020.000169
[19]	Zhou Y, Huang T, Siu HL, et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinoge-nesis[J]. Mol Cancer, 2017, 16(1): 77. DOI: 10.1186/s12943-017-0647-2. doi:10.1186/s12943-017-0647-2
[20]	李可心, 黄常志. IGF2BP3在肿瘤中作用的研究进展[C]// 中国生物化学与分子生物学会2019年全国学术会议暨学会成立四十周年论文集, 太原: 中国生物化学与分子生物学会, 2019: 91.
[21]	符白玉, 林怡, 徐琪, 等. 胃癌患者血清p53、PDCD-5、survivin表达水平及其联合应用的价值[J]. 分子诊断与治疗杂志, 2021, 13(4): 615-618, 622. DOI: 10.3969/j.issn.1674-6929.2021.04.027. doi:10.3969/j.issn.1674-6929.2021.04.027
[22]	Kim WJ, Kim W, Bae JM, et al. Dehydroabietic acid is a novel survivin inhibitor for gastric cancer[J]. Plants (Basel), 2021, 10(6): 1047. DOI: 10.3390/plants10061047. doi:10.3390/plants10061047
[23]	Wheatley SP, Altieri DC. Survivin at a glance[J]. J Cell Sci, 2019, 132(7): jcs223826. DOI: 10.1242/jcs.223826. doi:10.1242/jcs.223826
[24]	姚学权, 刘福坤, 祁晓萍, 等. 胃腺癌组织survivin基因的表达与细胞增殖及凋亡的相关性研究[J]. 中华外科杂志, 2004, 42(3): 145-148. DOI: 10.3760/j:issn:0529-5815.2004.03.005. doi:10.3760/j:issn:0529-5815.2004.03.005
[25]	Sun XP, Dong X, Lin L, et al. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer[J]. FEBS J, 2014, 281(1): 115-128. DOI: 10.1111/febs.12577. doi:10.1111/febs.12577
[26]	Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres[J]. BMC Cancer, 2008, 8: 266. DOI: 10.1186/1471-2407-8-266. doi:10.1186/1471-2407-8-266pmid:18803879
[27]	Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours[J]. Br J Cancer, 2020, 122(11): 1630-1637. DOI: 10.1038/s41416-020-0802-1. doi:10.1038/s41416-020-0802-1
[28]	Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin[J]. Med Oncol, 2012, 29(4): 2473-2480. DOI: 10.1007/s12032-011-0156-x. doi:10.1007/s12032-011-0156-xpmid:22246523
[29]	Than VT, Tran HTT, Ly DV, et al. Bioinformatic identification and expression analysis of the chicken B cell lymphoma (BCL) gene[J]. Genes Genomics, 2019, 41(10): 1195-1206. DOI: 10.1007/s13258-019-00849-z. doi:10.1007/s13258-019-00849-z
[30]	方宇, 王琳玲, 王海娟, 等. Survivin、 Bcl-2在胃癌组织中的表达及临床意义[J]. 肿瘤药学, 2021, 11(4): 474-479. DOI: 10.3969/j.issn.2095-1264.2021.04.14. doi:10.3969/j.issn.2095-1264.2021.04.14
[31]	杨百仞. miR-34a/miR-335对survivin的表达调控及在胃癌中的生物功能学研究[D]. 广州: 南方医科大学, 2016: 1-103. DOI: 10.7666/d.Y3117024. doi:10.7666/d.Y3117024
[32]	赵丽丽, 赵文文, 冯青青, 等. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710. DOI: 10.3760/cma.j.cn371439-20210813-00140. doi:10.3760/cma.j.cn371439-20210813-00140
[33]	Jayachandran J, Srinivasan H, Mani KP. Molecular mechanism involved in epithelial to mesenchymal transition[J]. Arch Biochem Biophys, 2021, 710: 108984. DOI: 10.1016/j.abb.2021.108984. doi:10.1016/j.abb.2021.108984
[34]	Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities[J]. Front Med, 2018, 12(4): 361-373. DOI: 10.1007/s11684-018-0656-6. doi:10.1007/s11684-018-0656-6
[35]	Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84. DOI: 10.1038/s41580-018-0080-4. doi:10.1038/s41580-018-0080-4
[36]	Yang Y, Li X, Du J, et al. Involvement of microRNAs-MMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with Helicobacter pylori[J]. Exp Cell Res, 2018, 367(2): 196-204. DOI: 10.1016/j.yexcr.2018.03.036. doi:S0014-4827(18)30196-4pmid:29604247
[37]	Dilek FH, Topak N, Aktepe F, et al. E-cadherin, beta-catenin adhesion complex and relation to matrilysin expression in pT3 rectosigmoid cancers[J]. Pathol Res Pract, 2008, 204(11): 809-815. DOI: 10.1016/j.prp.2008.05.010. doi:10.1016/j.prp.2008.05.010pmid:18674869
[38]	Dobriţoiu M, Stepan AE, Mărgăritescu C, et al. Immunoexpression of E-cadherin, P-cadherin and fibronectin in gastric carcinomas[J]. Rom J Morphol Embryol, 2019, 60(2): 573-579.
[39]	Cha YH, Kim NH, Park C, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling[J]. Cell Cycle, 2012, 11(7): 1273-1281. DOI: 10.4161/cc.19618. doi:10.4161/cc.19618pmid:22421157
[40]	Wieczorek-Szukala K, Lewinski A. The role of snail-1 in thyroid cancer—what we know so far[J]. J Clin Med, 2021, 10(11): 2324. DOI: 10.3390/jcm10112324. doi:10.3390/jcm10112324
[41]	Baulida J, Díaz VM, Herreros AG. Snail1: a transcriptional factor controlled at multiple levels[J]. J Clin Med, 2019, 8(6): 757. DOI: 10.3390/jcm8060757. doi:10.3390/jcm8060757
[42]	金丽, 耿敬姝. Snail蛋白表达与胃癌浸润转移的相关性研究[J]. 肿瘤预防与治疗, 2008, 21(1): 22-24. DOI: 10.3969/j.issn.1674-0904.2008.01.006. doi:10.3969/j.issn.1674-0904.2008.01.006
[43]	Siemens H, Jackstadt R, Hünten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions[J]. Cell Cycle, 2011, 10(24): 4256-4271. DOI: 10.4161/cc.10.24.18552. doi:10.4161/cc.10.24.18552pmid:22134354
[44]	Zhang Y, Yuan Y, Zhang Y, et al. SNHG7 accelerates cell migration and invasion through regulating miR-34a-Snail-EMT axis in gastric cancer[J]. Cell Cycle, 2020, 19(1): 142-152. DOI: 10.1080/15384101.2019.1699753. doi:10.1080/15384101.2019.1699753pmid:31814518
[45]	曹利勉. c-Myc通过长非编码RNA LAST调控细胞周期的机制研究[D]. 合肥: 中国科学技术大学, 2019.
[46]	刘德仁, 丁闯, 侍孝红, 等. c-Myc在人胃癌组织中的表达及其对胃癌细胞增殖、迁移和侵袭的影响[J]. 现代肿瘤医学, 2021, 29(20): 3526-3531. DOI: 10.3969/j.issn.1672-4992.2021.20.004. doi:10.3969/j.issn.1672-4992.2021.20.004
[47]	Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors[J]. Cancer Treat Rev, 2018, 62: 50-60. DOI: 10.1016/j.ctrv.2017.11.002. doi:S0305-7372(17)30187-1pmid:29169144
[48]	Jiang W, Wang D, Alraies A, et al. Wnt-GSK3 β/β-catenin regulates the differentiation of dental pulp stem cells into bladder smooth muscle cells[J]. Stem Cells Int, 2019, 2019: 8907570. DOI: 10.1155/2019/8907570. doi:10.1155/2019/8907570
[49]	Wei B, Cao J, Tian JH, et al. Mortalin maintains breast cancer stem cells stemness via activation of Wnt/GSK3β/β-catenin signa-ling pathway[J]. Am J Cancer Res, 2021, 11(6): 2696-2716. pmid:34249423
[50]	Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer[J]. Nat Rev Cancer, 2021, 21(1): 5-21. DOI: 10.1038/s41568-020-00307-z. doi:10.1038/s41568-020-00307-zpmid:33097916
[51]	李硕果, 孔国强, 高社干. GSK3β在贲门腺癌中的表达及临床意义[J]. 重庆医学, 2020, 49(17): 2882-2884, 2888. DOI: 10.3969/j.issn.1671-8348.2020.17.023. doi:10.3969/j.issn.1671-8348.2020.17.023
[52]	Pan J, Fan Z, Wang Z, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 52. DOI: 10.1186/s13046-019-1049-7. doi:10.1186/s13046-019-1049-7
[53]	Li X, Chen W, Yang C, et al. IGHG1 upregulation promoted gastric cancer malignancy via AKT/GSK-3β/β-catenin pathway[J]. Cancer Cell Int, 2021, 21(1): 397. DOI: 10.1186/s12935-021-02098-1. doi:10.1186/s12935-021-02098-1pmid:34315496
[54]	Wang G, Liu G, Ye Y, et al. Upregulation of miR-34a by diallyl disulfide suppresses invasion and induces apoptosis in SGC-7901 cells through inhibition of the PI3K/Akt signaling pathway[J]. Oncol Lett, 2016, 11(4): 2661-2667. DOI: 10.3892/ol.2016.4266. doi:10.3892/ol.2016.4266pmid:27073535
[55]	Zhang Q, Wang J, Li N, et al. miR-34a increases the sensitivity of colorectal cancer cells to 5-fluorouracil in vitro and in vivo[J]. Am J Cancer Res, 2018, 8(2): 280-290.
[56]	Lacombe J, Zenhausern F. Emergence of miR-34a in radiation therapy[J]. Crit Rev Oncol Hematol, 2017, 109: 69-78. DOI: 10.1016/j.critrevonc.2016.11.017. doi:S1040-8428(16)30351-1pmid:28010900
[57]	Beg MS, Brenner AJ, Sachdev J, et al. Phase Ⅰ study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors[J]. Invest New Drugs, 2017, 35(2): 180-188. DOI: 10.1007/s10637-016-0407-y. doi:10.1007/s10637-016-0407-y
[58]	Zhang Z, Kong Y, Yang W, et al. Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting Met[J]. Oncol Rep, 2016, 36(4): 2391-2397. DOI: 10.3892/or.2016.5016. doi:10.3892/or.2016.5016pmid:27513895
[59]	Song Z, Liang X, Wang Y, et al. Phenylboronic acid-functionalized polyamidoamine-mediated miR-34a delivery for the treatment of gastric cancer[J]. Biomater Sci, 2019, 7(4): 1632-1642. DOI: 10.1039/c8bm01385c. doi:10.1039/c8bm01385c